12:00 AM
 | 
Dec 07, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ToleroMune cat allergy therapy: Phase II data

In a double-blind, placebo-controlled, Canadian Phase II trial in 121 patients with cat allergies, the optimal regimen of ToleroMune decreased TRSS from baseline by 67% compared with placebo. ToleroMune also reduced nasal an ocular allergy symptom levels....

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >